Skip to main content

Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy

Objective

The goal of SYMPATH is to advance clinical development of therapeutic vaccines targeting α-synuclein (aSyn)-driven neurodegenerative diseases (ND). It addresses Parkinson’s disease (PD) and multiple system atrophy (MSA), two synucleopathies, for which no causal therapy exists. Ultimately, both lead to patient disability and death, which along with patient number (PD) and age of onset (MSA, PD) define their high medical need status.
The proposed programme focuses on 2 vaccine candidates, PD01A and PD03A, delivered by the innovative AFFITOME® technology. Both are peptide-protein conjugate vaccines and first-in-class candidates. They were selected to elicit antibodies neutralizing aSyn but sparing compensatory β-synuclein. Pre-clinical evaluation confirmed their disease-modifying activity in various models. The unprecedented clinical approach, called TANDEM strategy, uses the synergy resulting from applying 2 vaccine candidates in 2 complementary indications linked through their pathology. TANDEM PD/MSA capitalizes on (i) excellent clinical research centres and their associated national/European networks, (ii) platform methods assessing aSyn species as candidate biomarkers and (iii) preliminary clinical experience with PD01A, the first aSyn targeting vaccine ever tested in humans. Its core is formed by 2 phase I studies testing PD01A in MSA and PD03A in PD/MSA. Importantly, trial design (duration, endpoints, vaccine dose and schedule) will ensure collection of initial biomarker data connecting clinical results of PD- and MSA trajectories. SYMPATH defines the logical next development step of both AFFITOPE® vaccine candidates for synucleopathies and generates information/material (biobank) rendering them more amenable to rational drug development. Successful completion of the programme promises reaching aSyn pathology with an active vaccine as a causal therapy for PD/MSA, thus advancing one or both candidates as prime targets for product development and investment.

Field of science

  • /medical and health sciences/basic medicine/pathology
  • /medical and health sciences/basic medicine/neurology/parkinson
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

AFFIRIS AG
Address
Karl Farkas Gasse 22
1030 Wien
Austria
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 905 925
Administrative Contact
Vera Bürger (Mrs.)

Participants (7)

BIOLUTION GMBH
Austria
EU contribution
€ 685 011
Address
Helmut Qualtinger Gasse 2/2
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Iris Grünert (Dr.)
CHU HOPITAUX DE BORDEAUX
France
EU contribution
€ 342 712
Address
Rue Dubernat 12
33404 Talence
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jean-Jacques Jalibert (Mr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 173 503
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Muriel Bouas (Mrs.)
PROSENEX AMBULATORIUM BETRIEBSGMBH
Austria
EU contribution
€ 366 012
Address
Schottenfeldgasse 45
1070 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dieter Volc (Dr.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 366 012
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wolfram Rieneck (Dr.)
FORSCHUNGSZENTRUM JULICH GMBH
Germany
EU contribution
€ 789 322
Address
Wilhelm Johnen Strasse
52428 Julich
Activity type
Research Organisations
Administrative Contact
Anke Krüger (Mrs.)
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
France
EU contribution
€ 371 209
Address
Rue Viguerie 2 Hotel Dieu Saint Jacques
31052 Toulouse Cedex 3
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Corinne Joffre (Dr.)